Waters Corporation Announces MassTrak™ Clinical Solutions
Today clinical chemists around the globe demand the highest standards in analytical technologies. Thought leaders in medical research depend on reliable robust methodology, uncompromised accuracy and ease-of-use so that they can develop new tests. Waters Corporation announced today MassTrak Clinical Solutions, a systems approach aimed at clinical research applications to respond to the growing, complex needs of this demanding market.
Waters® MassTrak Clinical Solutions provide a comprehensive answer to monitor and measure drug therapies, perform toxicology screening and confirm and quantify biomarkers quickly, reliably and accurately. They include methodology, HPLC, mass spectrometry, software, chemistries and service and technical support from Waters worldwide clinical team.
The heart of Waters MassTrak Clinical Solutions is Waters LC/MS/MS technology encompassing the Quattro series of tandem mass spectrometers and the Alliance® series of HPLCs with software optimized for clinical research applications and methodology. The MassTrak Clinical Solutions approach enables researchers to measure trace levels of analytes with high specificity and sensitivity in a robust, high throughput system with simple sample preparation.
“The analysis of drugs in complex matrices requires the highest levels of speed, accuracy and sensitivity in a robust, easy-to-use system,” said Mike Yelle, Senior Director of Clinical Business Operations at Waters. “MassTrak Systems have been designed to bring the enabling benefits of LC/MS/MS technology to clinical research. We are committed to ensuring our customers’ success with complete solutions to improve the accuracy and precision of their assays.”
For more information on MassTrak Clinical Solutions, please visit www.waters.com/clinical and the Waters booths (21 and 22) at the International Association of Therapeutic Drug Monitoring and Clinical Toxicology conference in Louisville, Kentucky beginning April 24th.
About Waters Corporation
Waters Corporation holds worldwide leading positions in three complementary analytical technologies – liquid chromatography, mass spectrometry and thermal analysis. These markets account for $4.5 – $5.0 billion of the overall $20+ billion analytical instrument market.
NOTICE:
The MassTrak systems are CE marked and declared as in vitro diagnostic devices in the European Union under EU directive 98/79/EC. In the United States, these systems are not approved or cleared with the FDA for use in clinical diagnostic procedures. No use of these systems as diagnostic medical devices is implied or should be inferred.
Waters and Alliance are registered trademarks and MassTrak is a trademark of Waters Corporation.
